OstomyCure AS Appoints new Chief Medical Officer

January 31st, 2017, OSLO

OstomyCure today announced the appointment of Cindy Wong, M.D. as Chief Medical Officer (CMO). Dr Wong brings a wealth of experience to the company, especially in Post Market Surveys and FDA submissions.

OstomyCure, the Norwegian medical technology company, strengthens its organization with Cindy Wong as CMO. Dr Wong has an extensive international experience working with Class II and III medical devices from clinical development to device safety to regulatory submissions, authority inspections, risk management, post-market regulatory requirements and clinical studies and medical information. She will mainly focus on building, leading and developing the local medical information, device safety, marketing support, postmarket surveillance as well as medical activities for the product in accordance to internal and external regulations.

Dr Wong joins the company from Galderma Q-Med where she has been the CMO for Global Medical Affairs and prior to that at Q-Med since 2004. Among her responsibilities were building the global network and partnerships to take the lead to support the affiliates in performance of clinical studies and publications, device vigilance, meeting regulatory requirements for product registration and renewal, medical information and publications.

“We are delighted to have Dr. Wong join our team,” said Dr. Benedict Broennimann, Chief Executive Officer of OstomyCure.“ OstomyCure continues to expand its senior medical leadership in response to emerging global development opportunities. Cindy’s broad experience is well-suited to our clinical and commercial development efforts. We very much look forward to her contribution in the continued growth and development of our future pipeline and the company as a whole.

“I am so happy to have the opportunity to contribute to further development that will improve the quality of life of these patients who need medical care life-long”, Cindy Wong states.

OstomyCure has developed the TIES® System as a game changer for ileostomy patients. TIES® aim is to make life easier and dramatically increase the quality of life by helping those with a stoma to take back the control and live a more carefree life.

In addition, the innovative benefits for the patients, TIES® also provide considerable economic benefits. “Our preliminary calculations have shown that TIES® is a less expensive solution over time” says Dr. Broennimann, and concludes “It is our mission to provide better healthcare and better quality of life for the stoma users as well as cost benefits for the health care authorities and payers.”

Initially, the TIES® System will be launched in UK, Norway, Sweden and Germany.

Contact information:

Dr. Ben Broennimann, M.D.
CEO, OstomyCure AS
Phone: +41 79 301 6272
Email: ben@ostomycure.com

Nishant Fafalia
Chairman, OstomyCure AS
Phone +47 902 927 65
Email: nishant.fafalia@kistefos.no

Stockholm office:
Growhouse, Isafjordsgatan 39B
16440 KISTA, Sweden

OstomyCure AS
Oslo Science Park, Gaustadalléen
210349 OSLO, Norway

About OstomyCure:

OstomyCure AS is a Medical Technology company headquartered in Oslo, Norway. The company develops a revolutionary
technology; Transcutaneous Implant Evacuation System, The TIES® System.

The TIES® System is the result of several years of research combined with the latest 3D manufacturing technology,
developed and produced in accordance with regulatory standards to ensure safety for patients.

Since August 2011 the company is ISO 13485 certified for Quality Management System for Medical Devices.

The TIES® System is CE marked since June 2016.

The market that OstomyCure addresses is estimated to be USD 2 billion per year.

Leave a reply